Propecia

Propecia is the brand name for a 1 mg oral tablet of finasteride, a prescription medicine developed and marketed by Merck for men with male pattern hair loss, medically known as androgenetic alopecia. Finasteride inhibits type II 5-alpha-reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT). Lowering DHT in the scalp can slow miniaturization of susceptible hair follicles and promote or maintain hair growth in some men. The product emerged from research into finasteride at Merck. The same active ingredient was first commercialized at a higher strength as Proscar, a 5 mg tablet for benign prostatic hyperplasia. Clinical development subsequently examined whether a lower dose could address hair loss. The United States Food and Drug Administration approved Propecia in 1997 for the treatment of male pattern hair loss in men. It became one of the best-known prescription treatments for this condition and helped establish oral finasteride as a standard medical option alongside topical minoxidil. Propecia is not a general cosmetic supplement and is not indicated for women or children. Its use requires medical assessment because hair loss can have causes other than androgenetic alopecia, and finasteride affects the metabolism of sex hormones. The product is generally taken once daily, with treatment benefits requiring continued use; discontinuation typically leads to loss of the hair maintained or regrown through therapy over time. The branded product is distinct from Proscar, although both contain finasteride, and from generic finasteride products that became available after patent and regulatory exclusivity periods ended in various markets. Safety communication has been an important part of Propecia's public profile. Product labeling identifies sexual adverse reactions such as decreased libido, erectile dysfunction, and reduced ejaculate volume. Regulators and medical authorities have also considered reports of persistent sexual symptoms after discontinuation, mood changes, depression, and suicidal thoughts. The existence, frequency, causation, and clinical interpretation of some post-treatment reports have been debated, but these concerns have led to label revisions, pharmacovigilance activity, lawsuits, and continuing public scrutiny. In the United States, finasteride remains an approved prescription treatment, subject to physician counseling and the applicable label. Propecia is a product brand rather than a separately incorporated company. Merck has been its principal originator and brand owner, while generic manufacturers and pharmacies now offer finasteride 1 mg under non-branded names. Availability, labeling, reimbursement, and brand ownership arrangements can differ by country. The brand's commercial importance therefore reflects both its original role in prescription hair-loss treatment and the broader clinical use of finasteride in branded and generic forms.

Propecia developed from Merck's research into finasteride, a 5-alpha-reductase inhibitor. Merck originally investigated the compound for conditions associated with excessive DHT activity and introduced the higher-dose 5 mg formulation Proscar for benign prostatic hyperplasia. Observations that reduced DHT could influence hair growth led to clinical work on a lower-strength formulation for men with androgenetic alopecia. Merck's development program evaluated finasteride 1 mg in men with male pattern hair loss. The therapeutic rationale was that DHT contributes to the progressive shrinking of genetically susceptible scalp follicles. By inhibiting type II 5-alpha-reductase, finasteride lowers circulating and scalp DHT, although it does not permanently change the underlying genetic susceptibility. Clinical results supported improvements in hair counts and the slowing of further loss in some men, particularly in the crown and mid-scalp regions. The FDA approved Propecia in 1997. Its approval made a daily oral prescription a prominent treatment option for male pattern hair loss, a condition that had previously been addressed mainly through cosmetic measures, surgical transplantation, and topical minoxidil. Propecia's brand identity was built around medical treatment rather than hair-care retailing. Physicians generally prescribe it after assessing the pattern and likely cause of hair loss, and patients are counseled that benefits depend on continued treatment. The product's history has also been shaped by safety communication. The original and subsequent prescribing information has described sexual adverse reactions, including decreased libido, erectile dysfunction, and changes in ejaculation. Postmarketing reports and patient advocacy have drawn attention to symptoms that some users say continued after treatment stopped, as well as depression and suicidal thoughts. Regulators have responded through safety reviews, label language, and recommendations for patient and prescriber awareness. These developments have generated litigation and controversy, but they do not change the fact that finasteride remains an approved medicine in several jurisdictions. As regulatory exclusivity and patent protections expired in different markets, generic finasteride became widely available. This reduced the need for the branded product in many prescribing settings while extending access to the active ingredient. Propecia remains a recognizable reference brand, whereas current treatment may involve a generic 1 mg tablet, a branded product, or another therapy such as topical minoxidil. The brand is therefore best understood as an established pharmaceutical product within the wider finasteride market, not as a standalone company or a consumer hair-care business.

• 2024

  European safety review of finasteride and dutasteride

  [3]EMA referral: finasteride and dutasterideema.europa.eu

  The EMA initiated a review of measures for minimizing suicidal thoughts and other potential risks associated with finasteride- and dutasteride-containing medicines.

• 2022

  U.S. labeling reflects psychiatric safety concerns

  [1]Propecia U.S. prescribing informationaccessdata.fda.gov

  Current U.S. labeling materials include postmarketing reports involving depression and suicidal ideation along with established sexual adverse reactions.

• 2012

  U.S. label adds postmarketing sexual adverse-event information

  [6]U.S. label adds postmarketing sexual adverse-event informationaccessdata.fda.gov

  The prescribing information described reports of sexual dysfunction continuing after discontinuation in the postmarketing experience section.

• 1997

  Propecia receives U.S. approval

  [5]Propecia receives U.S. approvalaccessdata.fda.gov

  The FDA approved Propecia, a 1 mg finasteride tablet, for male pattern hair loss in men.

• 1992

  Finasteride is approved at 5 mg as Proscar

  [4]Proscar U.S. prescribing informationaccessdata.fda.gov

  Merck received U.S. approval for finasteride 5 mg under the Proscar brand for benign prostatic hyperplasia, establishing the active ingredient's initial major pharmaceutical use.

A physician-prescribed, evidence-based oral treatment for male pattern hair loss, positioned separately from cosmetic hair-care products, dietary supplements, and topical therapies.

• Prescription hair-loss medicine · 1997

  Propecia 1 mg tablets

  The core Propecia product is an oral tablet containing 1 mg of finasteride. It is indicated for men with male pattern hair loss and works by inhibiting type II 5-alpha-reductase, thereby reducing DHT. Treatment is generally taken once daily and requires ongoing use to maintain benefits. The product is prescription-only in the United States and many other markets. Equivalent generic finasteride 1 mg products are widely available.

• 2024

  Regulatory scrutiny of psychiatric effects

  European regulators reviewed reports involving suicidal thoughts and other psychiatric effects associated with finasteride medicines, including products used for hair loss. The review concerned risk minimization and product information rather than a general withdrawal of finasteride.

  Source

• 2012

  Persistent sexual side-effect controversy

  Patient reports, scientific debate, and litigation focused on claims that sexual symptoms associated with finasteride could persist after treatment ended. U.S. labeling incorporated postmarketing information, while the frequency and causal mechanism of persistent symptoms remained contested.

  Source

Read more

• 2024

  European review of finasteride safety measuresOther

  Background

  European authorities assessed reports of suicidal thoughts and other potential psychiatric and sexual adverse effects associated with finasteride and dutasteride.

  Action taken

  The EMA initiated a referral procedure to evaluate whether additional risk-minimization measures or product-information changes were needed.

  Aftermath

  The review kept psychiatric and sexual safety communication prominent for prescribers and patients while the regulatory assessment proceeded.

  Source

• 2012

  Expansion of postmarketing safety informationOther

  Background

  Reports from patients and postmarketing surveillance raised questions about sexual symptoms that might continue after discontinuation.

  Action taken

  U.S. prescribing information included additional postmarketing information concerning sexual dysfunction after treatment cessation.

  Aftermath

  The label change intensified counseling, pharmacovigilance, litigation, and public debate about finasteride's risk profile.

  Source

• 1997

  Launch of a lower-dose finasteride hair-loss formulationProduct launch

  Background

  Merck had established finasteride through the higher-dose Proscar product for benign prostatic hyperplasia and then developed a 1 mg formulation for male pattern hair loss.

  Action taken

  The company obtained FDA approval for Propecia 1 mg for male pattern hair loss in men.

  Aftermath

  Propecia became a leading reference brand for oral prescription treatment of male pattern hair loss, while generic finasteride later expanded competition.

  Source

1. 1Propecia U.S. prescribing informationaccessdata.fda.gov
2. 2FDA Drugs@FDA record for Propeciaaccessdata.fda.gov
3. 3EMA referral: finasteride and dutasterideema.europa.eu
4. 4Proscar U.S. prescribing informationaccessdata.fda.gov
5. 5Propecia receives U.S. approvalaccessdata.fda.gov
6. 6U.S. label adds postmarketing sexual adverse-event informationaccessdata.fda.gov